OBJECTIVE: Accumulating preclinical and epidemiologic evidence has emerged to suggest that modulation of cytochrome P450 (CYP)-mediated eicosanoid metabolism may be a viable vascular protective therapeutic strategy for the secondary prevention of coronary artery disease (CAD). The functional relationship between CYP-derived eicosanoid metabolite levels and vascular dysfunction in humans with established CAD, however, has not been evaluated. Therefore, we characterized the relationship between inter-individual variation in soluble epoxide hydrolase (sEH) and CYP ω-hydroxylase metabolism and established vascular function phenotypes predictive of prognosis in a cohort of patients with atherosclerotic cardiovascular disease. METHODS: Plasma epoxyeicosatrienoic acid (EET), dihydroxyeicosatrienoic acid (DHET), and 20-hydroxyeicosatetraenoic acid (20-HETE) levels were quantified by HPLC-MS/MS in 106 patients with stable, angiographically-confirmed CAD. Relationships between biomarkers of CYP-mediated eicosanoid metabolism and vascular function phenotypes were evaluated by Pearson's correlation. RESULTS: A significant inverse association was observed between 20-HETE levels (a biomarker of CYP ω-hydroxylase metabolism) and brachial artery flow-mediated dilation (r = -0.255, p = 0.010). An inverse association was also observed between 14,15-EET:DHET ratios (a biomarker of sEH metabolism) and both monocyte chemoattractant protein-1 levels (r = -0.252, p = 0.009) and a consolidated cellular adhesion molecule 'score' reflecting the levels of E-selectin and P-selectin (r = -0.216, p = 0.027). No associations with C-reactive protein or epithelial neutrophil-activating protein-78 levels were observed. CONCLUSIONS: Collectively, these findings demonstrate that enhanced CYP ω-hydroxylase and sEH metabolic function are associated with more advanced endothelial dysfunction and vascular inflammation, respectively, in patients with established atherosclerotic cardiovascular disease. These findings lay the foundation for future clinical research in this area.
OBJECTIVE: Accumulating preclinical and epidemiologic evidence has emerged to suggest that modulation of cytochrome P450 (CYP)-mediated eicosanoid metabolism may be a viable vascular protective therapeutic strategy for the secondary prevention of coronary artery disease (CAD). The functional relationship between CYP-derived eicosanoid metabolite levels and vascular dysfunction in humans with established CAD, however, has not been evaluated. Therefore, we characterized the relationship between inter-individual variation in soluble epoxide hydrolase (sEH) and CYP ω-hydroxylase metabolism and established vascular function phenotypes predictive of prognosis in a cohort of patients with atherosclerotic cardiovascular disease. METHODS: Plasma epoxyeicosatrienoic acid (EET), dihydroxyeicosatrienoic acid (DHET), and 20-hydroxyeicosatetraenoic acid (20-HETE) levels were quantified by HPLC-MS/MS in 106 patients with stable, angiographically-confirmed CAD. Relationships between biomarkers of CYP-mediated eicosanoid metabolism and vascular function phenotypes were evaluated by Pearson's correlation. RESULTS: A significant inverse association was observed between 20-HETE levels (a biomarker of CYP ω-hydroxylase metabolism) and brachial artery flow-mediated dilation (r = -0.255, p = 0.010). An inverse association was also observed between 14,15-EET:DHET ratios (a biomarker of sEH metabolism) and both monocyte chemoattractant protein-1 levels (r = -0.252, p = 0.009) and a consolidated cellular adhesion molecule 'score' reflecting the levels of E-selectin and P-selectin (r = -0.216, p = 0.027). No associations with C-reactive protein or epithelial neutrophil-activating protein-78 levels were observed. CONCLUSIONS: Collectively, these findings demonstrate that enhanced CYP ω-hydroxylase and sEH metabolic function are associated with more advanced endothelial dysfunction and vascular inflammation, respectively, in patients with established atherosclerotic cardiovascular disease. These findings lay the foundation for future clinical research in this area.
Authors: Dawn Chen; Randall Whitcomb; Euan MacIntyre; Vinh Tran; Zung N Do; James Sabry; Dinesh V Patel; Sampath K Anandan; Richard Gless; Heather K Webb Journal: J Clin Pharmacol Date: 2011-03-21 Impact factor: 3.126
Authors: John M Seubert; Christopher J Sinal; Joan Graves; Laura M DeGraff; J Alyce Bradbury; Craig R Lee; Kerry Goralski; Michelle A Carey; Ayala Luria; John W Newman; Bruce D Hammock; John R Falck; Holly Roberts; Howard A Rockman; Elizabeth Murphy; Darryl C Zeldin Journal: Circ Res Date: 2006-07-20 Impact factor: 17.367
Authors: R P Tracy; B M Psaty; E Macy; E G Bovill; M Cushman; E S Cornell; L H Kuller Journal: Arterioscler Thromb Vasc Biol Date: 1997-10 Impact factor: 8.311
Authors: Natalie C Ward; Jennifer Rivera; Jonathan Hodgson; Ian B Puddey; Lawrie J Beilin; John R Falck; Kevin D Croft Journal: Circulation Date: 2004-07-19 Impact factor: 29.690
Authors: Jennifer Cheng; Cheng-Chia Wu; Katherine H Gotlinger; Frank Zhang; John R Falck; Dubasi Narsimhaswamy; Michal Laniado Schwartzman Journal: J Pharmacol Exp Ther Date: 2009-10-19 Impact factor: 4.030
Authors: Tsuneo Ishizuka; Jennifer Cheng; Harpreet Singh; Marco D Vitto; Vijay L Manthati; John R Falck; Michal Laniado-Schwartzman Journal: J Pharmacol Exp Ther Date: 2007-10-18 Impact factor: 4.030
Authors: Natalie C Ward; I-Jung Tsai; Anne Barden; Frank M van Bockxmeer; Ian B Puddey; Jonathan M Hodgson; Kevin D Croft Journal: Hypertension Date: 2008-04-07 Impact factor: 10.190
Authors: Yangmei Deng; Matthew L Edin; Katherine N Theken; Robert N Schuck; Gordon P Flake; M Alison Kannon; Laura M DeGraff; Fred B Lih; Julie Foley; J Alyce Bradbury; Joan P Graves; Kenneth B Tomer; John R Falck; Darryl C Zeldin; Craig R Lee Journal: FASEB J Date: 2010-11-08 Impact factor: 5.191
Authors: Jonas Bystrom; Jessica A Wray; Mary C Sugden; Mark J Holness; Karen E Swales; Timothy D Warner; Matthew L Edin; Darryl C Zeldin; Derek W Gilroy; David Bishop-Bailey Journal: PLoS One Date: 2011-10-19 Impact factor: 3.240
Authors: Samantha L Hoopes; Victor Garcia; Matthew L Edin; Michal L Schwartzman; Darryl C Zeldin Journal: Prostaglandins Other Lipid Mediat Date: 2015-03-23 Impact factor: 3.072
Authors: Yan Ding; Cheng-Chia Wu; Victor Garcia; Irina Dimitrova; Adam Weidenhammer; Gregory Joseph; Frank Zhang; Vijay L Manthati; John R Falck; Jorge H Capdevila; Michal L Schwartzman Journal: Am J Physiol Renal Physiol Date: 2013-07-03
Authors: Xinping Liu; Sung Ho Moon; David J Mancuso; Christopher M Jenkins; Shaoping Guan; Harold F Sims; Richard W Gross Journal: Anal Biochem Date: 2013-07-11 Impact factor: 3.365
Authors: Šárka Jíchová; Libor Kopkan; Zuzana Husková; Šárka Doleželová; Jan Neckář; Petr Kujal; Zdenka Vernerová; Herbert J Kramer; Janusz Sadowski; Elzbieta Kompanowska-Jezierska; Rami N Reddy; John R Falck; John D Imig; Luděk Červenka Journal: J Hypertens Date: 2016-10 Impact factor: 4.844
Authors: Christi M Terry; Mary L Carlson; Yuxia He; Arzu Ulu; Christophe Morisseau; Donald K Blumenthal; Bruce D Hammock; Alfred K Cheung Journal: J Vasc Res Date: 2014-09-05 Impact factor: 1.934
Authors: Jennifer Cheng; Matthew L Edin; Samantha L Hoopes; Hong Li; J Alyce Bradbury; Joan P Graves; Laura M DeGraff; Fred B Lih; Victor Garcia; Jafar Sadik B Shaik; Kenneth B Tomer; Gordon P Flake; John R Falck; Craig R Lee; Samuel M Poloyac; Michal L Schwartzman; Darryl C Zeldin Journal: FASEB J Date: 2014-03-25 Impact factor: 5.191
Authors: Nan Wang; Kimberly C Vendrov; Brian P Simmons; Robert N Schuck; George A Stouffer; Craig R Lee Journal: Prostaglandins Other Lipid Mediat Date: 2017-11-16 Impact factor: 3.072